Emerging Options After Progression During Crizotinib Therapy
- PMID: 26712224
- DOI: 10.1200/JCO.2015.65.1406
Emerging Options After Progression During Crizotinib Therapy
Comment on
-
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/jco.2015.63.9443. Epub 2015 Nov 23. J Clin Oncol. 2016. PMID: 26598747 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical